Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.23 Average PT from Analysts

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $3.2250.

LXRX has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Tuesday, September 2nd. Citigroup increased their price target on shares of Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Wall Street Zen raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, October 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 8th.

Lexicon Pharmaceuticals Stock Up 7.0%

LXRX stock opened at $1.52 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.16 and a quick ratio of 4.16. The firm has a market capitalization of $552.37 million, a P/E ratio of -4.61 and a beta of 1.23. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.08. The company’s 50 day simple moving average is $1.25 and its 200-day simple moving average is $0.96.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The company had revenue of $28.87 million for the quarter, compared to the consensus estimate of $4.87 million. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. As a group, equities research analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Hudson Bay Capital Management LP purchased a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $26,000. Cerity Partners LLC grew its stake in shares of Lexicon Pharmaceuticals by 21.1% in the 2nd quarter. Cerity Partners LLC now owns 206,279 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 35,892 shares in the last quarter. Invesco Ltd. increased its holdings in Lexicon Pharmaceuticals by 47.2% in the second quarter. Invesco Ltd. now owns 420,700 shares of the biopharmaceutical company’s stock worth $398,000 after buying an additional 134,941 shares during the last quarter. XTX Topco Ltd raised its position in Lexicon Pharmaceuticals by 431.4% during the second quarter. XTX Topco Ltd now owns 66,276 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 53,805 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd bought a new position in Lexicon Pharmaceuticals during the second quarter valued at approximately $51,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.